Clinical Trials Logo

Rhinitis clinical trials

View clinical trials related to Rhinitis.

Filter by:

NCT ID: NCT03097432 Completed - Clinical trials for Seasonal Allergic Rhinitis

Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Start date: October 20, 2016
Phase: N/A
Study type: Observational

This prospective open multi-centre non-interventional study initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes are freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B is performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician`s office and continuation at the patient`s home also exclusively using the highest solution strength and takes 4 days. Data are documented by physicians and in patients´ diaries.

NCT ID: NCT03070288 Completed - Allergic Rhinitis Clinical Trials

RGB(Red- Green-Blue) Measurement of the Nasal Mucosal Image

Start date: February 1, 2018
Phase:
Study type: Observational

The aim of this study was to evaluate the color values of the nasal mucosa, which is easily assessable by a direct, non-invasive, objective photographic measurement, for the purpose of presenting a diagnostic objective parameter of allergic rhinitis (AR). All patients and controls were examined by the same 4 mm 0ā°endoscope and light source, and all endoscopic photographs of the septum and both inferior turbinates were taken. Adobe Photoshop Elements 7.0 program was used to measure the numerical values of the red-green-blue (RGB) color components in endoscopic photographs of the nasal mucosa on the septum and inferior turbinates.

NCT ID: NCT03039816 Completed - Allergic Rhinitis Clinical Trials

Cellulose Powder Against Grass Pollen Allergic Rhinitis

CPARGPDBPC
Start date: May 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Background: A nasally applied cellulose powder is increasingly used in many countries as a remedy for allergic rhinitis. In 2009, a 4-week study in birch pollen-allergic children showed a reduction in nasal symptoms. The best effect occurred on days with lower pollen counts. The present study in grass pollen-allergic adults used the same basic design. Methods: In May 2013, a double-blind, placebo-controlled study was conducted in 108 patients with allergic rhinitis due to grass pollen (18-40 years of age). SMS on mobile phones were used as reminders of treatment and reporting of symptom scores.

NCT ID: NCT03014661 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Untersuchung Zur Erfassung Und Kontrolle Der Lebensqualität Unter Einer Therapie Mit Pollinex Quattro Bei Heuschnupfen

Start date: June 2015
Phase: N/A
Study type: Observational

Questionnaire to measure and control the quality of life of patients with hay fever who are treated or were treated with Pollinex quattro

NCT ID: NCT03004131 Completed - Clinical trials for Seasonal Allergic Rhinitis

MP-AzeFlu Allergen Chamber - Onset of Action Study

Start date: January 7, 2017
Phase: Phase 4
Study type: Interventional

This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).

NCT ID: NCT02975479 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Intralymphatic Immunotherapy in Increasing Doses, Substudy

Start date: May 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The study evaluates the safety and effect of intralymphatic allergen specific immunotherapy in increasing doses. Patients with allergy to grass or birch will be treated with three intralymphatic injections in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U and 10 000 SQ-U, or placebo. ***IMPORTANT INFORMATION!*** The up-dosing protocol is changed due to adverse events at 5000 SQ-U. One patient had general utricaria 15 minutes after injection (moderate reaction). One patient had a serious adverse event with anaphylactic reaction 6 minutes after intralymphatic injection. (1000 SQ-U and 3000 SQ-U have been given with no serious adverse events.) New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U.

NCT ID: NCT02943720 Completed - Allergic Rhinitis Clinical Trials

ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen

ATIBAR
Start date: September 2016
Phase: Phase 2
Study type: Interventional

A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis

NCT ID: NCT02932774 Completed - Allergic Rhinitis Clinical Trials

Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

Start date: March 2001
Phase: Phase 4
Study type: Interventional

The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.

NCT ID: NCT02910401 Completed - Asthma Clinical Trials

Clinical Response to Rhinovirus Challenge

Start date: September 2016
Phase: Phase 2
Study type: Interventional

Rhinovirus (RV) infections represent the most common cause of asthma exacerbations in children and adolescents. The investigators hypothesize that the immune responses generated in the nose of allergic rhinitics and asthmatics underlie subsequent systemic modulation of the immune system, and that - in susceptible individuals (i.e., those with pre-existing asthma) - this modified nasal milieu is responsible for the asthma exacerbation. Open label single center study in asthmatics as well as allergic rhinitis (AR) and healthy controls. All subjects will undergo good manufacturing practice (GMP) RV16 inoculation and responses will be compared between the 3 cohorts.

NCT ID: NCT02908360 Completed - Atopic Dermatitis Clinical Trials

Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis

Prévall-DP
Start date: July 10, 2015
Phase:
Study type: Observational

The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and food allergy) has increased dramatically in industrialized countries over the last 20-30 years. Allergic diseases are present especially in children and young adults, but all age groups are affected, with variations across countries and age. To propose new therapies, the investigators must first understand the physiopathology. Since their discovery the regulatory T cells have continued to be the subject of work to understand their role in maintaining immune homeostasis in the human body but also their involvement in autoimmune diseases, inflammatory diseases, transplants of solid organs or fluids and allergic diseases. It was identified two broad classes of regulatory T cells: - T cells = natural regulators acquisition of a phenotype and a regulatory function right out of the thymus ( CD25 + / CD127 + low / FoxP3 +). - T cells induced regulators = acquisition of a phenotype and a regulatory function on the periphery depending on the cytokine micro-environment. Phenotypic characterization of these is less obvious and even more so than during the last ten years several induced regulatory T cell populations have been described ( eg, Tr1 ). A new subpopulation of T cells induced in patients with inflammatory bowel disease recently identified have a particular phenotype as bearing the CD4 and CD8 double marking with a regulatory phenotype. These regulatory T cells are also induced a specific of a commensal intestinal bacterium (Faecalibacterium prausnitzii). Regarding allergies, it has been widely demonstrated a relationship between changes of the intestinal microbiota and the occurrence of allergic diseases. The investigators would therefore propose a cross-sectional study, single-center, controlled, single blinded to study the role of T cells called double positive induced regulators DP8 to compare the frequency and the regulatory function of specific DP8 of Faecalibacterium prausnitzii in atopic dermatitis, asthma and allergic rhinitis compared to control samples.